These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22930789)

  • 21. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
    Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropsychological outcomes across the day in children with attention-deficit/hyperactivity disorder treated with atomoxetine: results from a placebo-controlled study using a computer-based continuous performance test combined with an infra-red motion-tracking device.
    Wehmeier PM; Schacht A; Wolff C; Otto WR; Dittmann RW; Banaschewski T
    J Child Adolesc Psychopharmacol; 2011 Oct; 21(5):433-44. PubMed ID: 22040189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
    Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity.
    Spencer TJ; Faraone SV; Michelson D; Adler LA; Reimherr FW; Glatt SJ; Biederman J
    J Clin Psychiatry; 2006 Mar; 67(3):415-20. PubMed ID: 16649828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders?
    Connor DF; Doerfler LA
    J Atten Disord; 2008 Sep; 12(2):126-34. PubMed ID: 17934178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A systematic review of the use of atomoxetine for management of comorbid anxiety disorders in children and adolescents with attention-deficit hyperactivity disorder.
    Khoodoruth MAS; Ouanes S; Khan YS
    Res Dev Disabil; 2022 Sep; 128():104275. PubMed ID: 35691145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atomoxetine in Attention-Deficit/Hyperactivity Disorder in Children With and Without Comorbid Mood Disorders.
    Shaker NM; Osama Y; Barakat DH; Abdelgawad AA; Abdel Aziz K; Aly El-Gabry D
    J Child Adolesc Psychopharmacol; 2021 Jun; 31(5):332-341. PubMed ID: 34143680
    [No Abstract]   [Full Text] [Related]  

  • 35. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial.
    Adler LA; Spencer T; Brown TE; Holdnack J; Saylor K; Schuh K; Trzepacz PT; Williams DW; Kelsey D
    J Clin Psychopharmacol; 2009 Feb; 29(1):44-50. PubMed ID: 19142107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Disruptive Behavior Disorders on Academic Performance and School Functions of Youths with Attention-Deficit/Hyperactivity Disorder.
    Liu CY; Huang WL; Kao WC; Gau SS
    Child Psychiatry Hum Dev; 2017 Dec; 48(6):870-880. PubMed ID: 28168530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical precursors of adolescent conduct disorder in children with attention-deficit/hyperactivity disorder.
    Whittinger NS; Langley K; Fowler TA; Thomas HV; Thapar A
    J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):179-87. PubMed ID: 17242621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atomoxetine-Related Change in Sluggish Cognitive Tempo Is Partially Independent of Change in Attention-Deficit/Hyperactivity Disorder Inattentive Symptoms.
    McBurnett K; Clemow D; Williams D; Villodas M; Wietecha L; Barkley R
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):38-42. PubMed ID: 27845858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atomoxetine for treating ADHD symptoms in autism: a systematic review.
    Ghanizadeh A
    J Atten Disord; 2013 Nov; 17(8):635-40. PubMed ID: 22544388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study.
    Biederman J; Petty CR; Dolan C; Hughes S; Mick E; Monuteaux MC; Faraone SV
    Psychol Med; 2008 Jul; 38(7):1027-36. PubMed ID: 18205967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.